WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407833

CAS#: 2225902-88-3

Description: CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Chemical Structure

CAS# 2225902-88-3

Theoretical Analysis

MedKoo Cat#: 407833
Name: CMP3a
CAS#: 2225902-88-3
Chemical Formula: C28H27F3N6O2S
Exact Mass: 568.1868
Molecular Weight: 568.6192
Elemental Analysis: C, 59.14; H, 4.79; F, 10.02; N, 14.78; O, 5.63; S, 5.64

Price and Availability

Size Price Availability Quantity
5.0mg USD 350.0 Same day
10.0mg USD 550.0 Same day
25.0mg USD 1150.0 Same day
50.0mg USD 2050.0 Same day
Bulk inquiry

Synonym: CMP3a; CMP-3a; CMP 3a.

IUPAC/Chemical Name: (R)-5-{7-[1-(2-Dimethylamino-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}-3-[1-(2-trifluoromethyl-phenyl)-ethoxy]-thiophene-2-carboxamide


InChi Code: InChI=1S/C28H27F3N6O2S/c1-17(20-6-4-5-7-21(20)28(29,30)31)39-23-13-24(40-26(23)27(32)38)22-15-33-25-12-18(8-9-37(22)25)19-14-34-36(16-19)11-10-35(2)3/h4-9,12-17H,10-11H2,1-3H3,(H2,32,38)/t17-/m1/s1

SMILES Code: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(C3=CN=C4C=C(C5=CN(CCN(C)C)N=C5)C=CN43)S1)N

Appearance: Yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 568.6192 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A,
Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum
HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and
radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest.
2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24. PubMed
PMID: 28737508; PubMed Central PMCID: PMC5531394.


5.0mg / USD 350.0

Additional Information

NEK2 was among the most differentially expressed kinase-encoding genes in GSC-containing cultures (glioma spheres), and it was required for in vitro clonogenicity, in vivo tumor propagation, and radioresistance. Mechanistically, the formation of a protein complex comprising NEK2 and EZH2 in glioma spheres phosphorylated and then protected EZH2 from ubiquitination-dependent protein degradation in a NEK2 kinase activity-dependent manner. Clinically, NEK2 expression in patients with glioma was closely associated with EZH2 expression and correlated with a poor prognosis. NEK2 expression was also substantially elevated in recurrent tumors after therapeutic failure compared with primary untreated tumors in matched GBM patients.